NCDMV warns of text payment scams
ROCKY MOUNT, N.C. (WNCT) — The N. C. Division of Motor Vehicles is alerting the public about a surge in fraudulent text message scams targeting residents.
According to a NCDOT press statement, these scams falsely claim to request payment for fees, fines, or tolls and may appear to come from the NCDMV.
Citizens are urged to report any suspicious texts as spam and delete them immediately. Do not click on any links or provide personal information in response to these messages.
NCDOT tips to protect yourself from scams:
Be cautious of unsolicited texts requesting payment or personal information.
Verify any NCDMV-related inquiries through official channels.
Report suspicious texts to your mobile carrier or the Federal Trade Commission at www.ftc.gov/complaint.
Learn more about how to identify phishing texts and scams at https://ncdoj.gov/internet-safety/phishing/.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
2 days ago
- Los Angeles Times
ICE flights out of L.A. area more than doubled in the last month
Flights out of Los Angeles area airports related to U.S. Immigration and Customs Enforcement deportations more than doubled in the month before Sunday. ICE increased its activity in the region this month, conducting multiple raids, including one on June 6 in the Fashion District. As a result of the raids, 330 people have been arrested as of June 11, according to the White House, some of whom were flown out of the area. ICE hasn't released many details regarding detainees. An ICE spokesperson told The Times that the agency does not provide details about future flights for security reasons. 'ICE field offices coordinate with ICE Air Operations, headquartered in Mesa, Ariz., to arrange removal travel and domestic transfers, which are conducted using both commercial airlines and ICE Air charter aircraft,' the spokesperson said in an email. The Times reviewed and analyzed public flight data compiled by Tom Cartwright, a volunteer immigration advocate at Witness at the Border who tracks ICE flights. Cartwright has tracked about 36,000 ICE flights over five years by using publicly available plane details and flight patterns. Since the June raids began, nearly 70% of deportation-related flights out of the L.A. region have originated out of the Southern California Logistics Airport in Victorville, near the Adelanto ICE Processing Center. The airport in Victorville is a public-use airport where charter airlines can operate nonscheduled private flights. Sue Jones, a spokesperson for Victorville, told The Times that because flight details are not tracked, the city cannot confirm ICE-related activity. There have also been reports of flights out of the Los Angeles area departing from other airports, including Burbank International and Meadows Field in Bakersfield. Since June 6, a quarter of the flights have gone directly to nearby Phoenix-Mesa Gateway Airport. About a fifth of flights head to El Paso, where the Mexican Consulate told The Times that some seized in L.A. are being detained. In addition to its headquarters, ICE Air Operations operates primarily from Miami; Alexandria, La.; and San Antonio and Brownsville, Texas. Charter planes making ICE-related flights can make multiple stops or transfers in a day, both inside and outside the United States. However, the journey the passengers take — where they board and disembark — cannot be tracked using publicly available data. Overall, from Jan. 1 through May, ICE has made 685 deportation stops to more than 30 international destinations, according to Witness at the Border's latest report. Roughly the same as the same time last year. ICE confirmed to The Times that the agency regularly flies deportees to countries in Central America, including Guatemala, El Salvador and Honduras, as well as other parts of the world 'for special high-risk missions.' For planes flying through Victorville, some made stops later at airports in cities such as Las Vegas, Salt Lake City and Harlingen, Texas. Other destinations outside the continental U.S. include: San Juan, Puerto Rico; San Pedro Sula, Honduras; Tapachula, Mexico; Guatemala City; Punta Cana, Dominican Republic; and Santo Domingo, Dominican Republic.
Yahoo
3 days ago
- Yahoo
Human Papillomavirus (HPV) Vaccines Strategic Business Research Report 2024-2025 & 2030 - Rising Global Awareness of HPV-Linked Cervical and Oropharyngeal Cancers Drives Preventive Vaccination Uptake
The global Human Papillomavirus (HPV) Vaccines market, valued at USD 5.5 billion in 2024, is anticipated to grow to USD 9.7 billion by 2030 at a CAGR of 9.9%. This report offers comprehensive analysis of market trends and growth drivers, providing vital insights for businesses. Key highlights include the evolution of vaccine formulations, such as nonavalent vaccines targeting multiple HPV strains, which are crucial in preventing HPV-related cancers globally. Strategic vaccination programs and improved distribution strategies are driving market expansion, particularly in emerging economies. Despite barriers like misinformation and hesitancy, increased public awareness and partnerships with organizations like Gavi are expected to enhance uptake, especially in high-burden regions. The report also assesses the impact of global tariff developments on the HPV vaccines market. Human Papillomavirus (HPV) Vaccines Market Dublin, June 19, 2025 (GLOBE NEWSWIRE) -- The "Human Papillomavirus (HPV) Vaccines - Global Strategic Business Report" report has been added to global market for Human Papillomavirus (HPV) Vaccines was estimated at US$5.5 Billion in 2024 and is projected to reach US$9.7 Billion by 2030, growing at a CAGR of 9.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Human Papillomavirus (HPV) Vaccines market. Human papillomavirus (HPV) vaccines play a central role in the prevention of HPV-related cancers, including cervical, oropharyngeal, anal, and genital cancers. With over 200 types of HPV identified and high-risk strains such as HPV-16 and HPV-18 accounting for the majority of cervical cancer cases, widespread immunization is viewed as a cornerstone of global cancer prevention strategies. These vaccines stimulate the immune system to develop antibodies against targeted viral strains, offering long-term protection against persistent infections and precancerous lesions. The Growth in the HPV Vaccines Market Is Driven by Several is driven by increasing global efforts to prevent HPV-related cancers, expansion of immunization programs, and the availability of broad-spectrum vaccine formulations. Rising public health investment in women's health and cancer prevention, along with WHO's cervical cancer elimination strategy, is catalyzing demand. The inclusion of boys in vaccination programs and growing incidence of HPV-linked head and neck cancers are further expanding the addressable progress in vaccine efficacy, long-term protection data, and potential single-dose regimens is supporting broader implementation. Additionally, partnerships between governments, vaccine developers, and health organizations are enhancing procurement, education, and infrastructure especially in emerging markets. Digital health platforms and mHealth campaigns are also improving outreach and record tracking, increasing vaccine uptake. Collectively, these trends are reinforcing HPV vaccines as a critical tool in global disease prevention and a dynamic segment within the broader vaccines Are Vaccine Formulations and Distribution Strategies Evolving?HPV vaccines have progressed from bivalent formulations (targeting HPV-16 and 18) to quadrivalent (adding protection against HPV-6 and 11) and now to nonavalent vaccines, which protect against nine HPV strains, including those responsible for up to 90% of cervical cancers. These broader-spectrum vaccines offer greater coverage and are expected to dominate future procurement and immunization programs. Continuous innovation in recombinant vaccine production and adjuvant systems is enhancing immune response and duration of is being optimized through school-based vaccination programs, gender-neutral campaigns, and integration with national childhood immunization schedules. Advances in cold-chain infrastructure, coupled with partnerships between governments, NGOs, and vaccine manufacturers, are improving access in low- and middle-income countries. Single-dose regimens are also under investigation as a cost-effective and logistically simpler alternative, with promising results that may reshape vaccination protocol and broaden global Is Uptake Increasing and What Barriers Remain?Vaccination uptake is rising in North America, Europe, and parts of Asia-Pacific where public awareness, healthcare infrastructure, and policy support are strong. Gender-neutral vaccination strategies are gaining traction, particularly in countries prioritizing the prevention of head and neck cancers linked to HPV in males. Latin America and Sub-Saharan Africa, despite high HPV burden, still face challenges including supply limitations, healthcare access gaps, and cultural include misinformation, vaccine hesitancy, and inconsistent public health messaging, particularly in conservative or resource-constrained regions. Limited adult vaccination programs and affordability issues also hamper broader market penetration. However, partnerships with organizations such as Gavi, the Vaccine Alliance, are actively addressing supply inequities and financial barriers through tiered pricing and donor-funded initiatives. As these issues are mitigated, market growth is expected to accelerate, particularly in high-burden Insights: Market Growth: Understand the significant growth trajectory of the Tetravalent segment, which is expected to reach US$5.8 Billion by 2030 with a CAGR of a 9.5%. The Nonavalent segment is also set to grow at 11.3% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $1.5 Billion in 2024, and China, forecasted to grow at an impressive 13.4% CAGR to reach $2.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Barinthus Biotherapeutics, Bharat Biotech, BioNTech SE, CanSino Biologics Inc., and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include: Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs. Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015. Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends. Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape. Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players. Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities. Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage. Key Attributes: Report Attribute Details No. of Pages 279 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $5.5 Billion Forecasted Market Value (USD) by 2030 $9.7 Billion Compound Annual Growth Rate 9.9% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Human Papillomavirus (HPV) Vaccines - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Global Awareness of HPV-Linked Cervical and Oropharyngeal Cancers Drives Preventive Vaccination Uptake Inclusion of HPV Vaccines in National Immunization Programs Expands Coverage Across Adolescents and Young Adults WHO and GAVI Support for HPV Vaccine Rollout in Low-Income Countries Strengthens Public Health Impact Expansion of Gender-Neutral Vaccination Policies Fuels Demand Across Male and Female Populations Technological Advancements in Vaccine Formulations Improve Long-Term Efficacy and Broaden Strain Coverage Increased School-Based Immunization Drives High Compliance Rates in Developed and Emerging Regions Public-Private Partnerships and Awareness Campaigns Boost Community-Level Vaccine Acceptance Improved Cold Chain Infrastructure and Global Procurement Facilitate Distribution to Remote Areas Rising Incidence of HPV-Associated Head and Neck Cancers Spurs Broader Advocacy for Adult Vaccination Growing Market Entry of Biosimilar and Region-Specific HPV Vaccines Enhances Accessibility and Affordability FOCUS ON SELECT PLAYERS Barinthus Biotherapeutics Bharat Biotech BioNTech SE CanSino Biologics Inc. GlaxoSmithKline plc Inovio Pharmaceuticals Johnson & Johnson Merck & Co., Inc. Moderna, Inc. Novavax, Inc. Pfizer Inc. Sanofi S.A. Serum Institute of India Sinovac Biotech Ltd. Takeda Pharmaceutical Company Valneva SE Vaxart, Inc. Walvax Biotechnology Co., Ltd. Wantai BioPharm Xiamen Innovax Biotech Co., Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Papillomavirus (HPV) Vaccines Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Los Angeles Times
3 days ago
- Los Angeles Times
R. Kelly is hospitalized and lawyer blames alleged murder plot. Feds call the allegations ‘fanciful'
R. Kelly collapsed in prison Friday and had to be hospitalized outside prison walls, then didn't get care that hospital staff said he needed, his attorney alleged in a Monday court filing. The disgraced R&B singer's attorney said federal prison officials attempted to kill Kelly via a drug overdose Friday, two days after a previous motion was filed stating that the 'I Believe I Can Fly' singer was in danger from an interstate plot involving prison authorities and the Aryan Brotherhood prison gang. Authorities are allegedly trying to prevent Kelly from spilling compromising information about misconduct by the Department of Justice and the Bureau of Prisons, per court documents filed on Kelly's behalf and reviewed by The Times. The federal government dismissed the intentional overdose allegations, filing a response Tuesday that characterized the idea of a prison murder plot as 'fantastic' and 'fanciful.' Kelly, 58, is serving 30-year and 20-year federal sentences that are largely concurrent at the FCI Butner prison facility in North Carolina after convictions in Illinois and New York on charges of child sex crimes and racketeering. Last week, attorney Beau B. Brindley filed an emergency furlough request on the singer's behalf, stating that he was the target of a BOP-related murder plot involving a member or members of the racist Aryan Brotherhood being told to order his killing. The filing included a sworn declaration from Brotherhood honcho Mikeal Glenn Stine, who has been incarcerated since 1982 and said he chose to come clean to Kelly about the alleged plot because he is 'a dying man' with terminal cancer and wanted BOP officials to be held accountable for decades of using inmates for their own purposes. The solution? Brindley asked that his client to be sent to home detention for an unspecified amount of time until the threat is gone. The filing insisted that time was 'of the essence' in a plot that allegedly was hatched in February 2023. That threat, he said in the Monday filing, loomed larger than ever after Kelly was taken to solitary confinement early last week with medicines for sleep and anxiety in his possession, then was given additional medications by prison officials along with instructions on how to take them. Brindley said he filed the initial motion alleging the murder plot two days after that, on June 12. 'In the early morning hours of June 13, 2025, Mr. Kelly awoke,' the additional Monday motion said. 'He felt faint. He was dizzy. He started to see black spots in his vision. Mr. Kelly tried to get up, but fell to the ground. He crawled to the door of the cell and lost consciousness. He was placed on a gurney. Prison officials wanted him to be taken to the on-site medical facility, but staff there could not assist him. Consequently, Mr. Kelly was taken by ambulance to nearby Duke University Hospital. While in the ambulance, he heard one of the prison officers with him state: 'this is going to open a whole new can of worms.'' Kelly learned at the hospital that he had been given a life-threatening overdose amount of medication, Brindley said in the Monday motion. The singer was hospitalized for two days for treatment. '[W]ithin two days of the filing of his [initial] motion, Bureau of Prisons officials administered an amount of medication that significantly exceeded a safe dose and caused Mr. Kelly to overdose, putting his life in jeopardy. They gave him an amount of medicine that could have killed him,' the Monday motion said. In a response to the Kelly team's initial filing from last week, prosecutors said Tuesday that the singer was asking the court to let him go home indefinitely 'under the guise of a fanciful conspiracy.' They argued that the district court in Illinois doesn't have jurisdiction over Kelly's request for a change in his sentence and therefore need not consider the request. 'The government disputes the fantastic allegations in Kelly's motion,' U.S. Atty. Andrew S. Boutros wrote. 'Kelly is in prison because he is a serial child molester whose criminal abuse of children dates back to at least President Clinton's first term in office — decades before Kelly was taken into federal custody.' Kelly's legal team doubled down on its allegations Tuesday in a reply to that government response, alleging that 'the Federal Bureau of Prisons is taking active steps to kill Robert Kelly' and had 'overdosed Mr. Kelly on medications and nearly killed him,' then 'took him out of a hospital at gunpoint and denied him surgery on blood clots in his lungs that the hospital said needed immediate intervention.' The blood clots reference was related to an allegation that Kelly had been seeking medical care for a swollen leg but had been denied. 'The government doesn't care if R. Kelly is killed in the Bureau of Prisons,' Brindley said in his Tuesday reply. 'They don't care if he dies in solitary confinement. That is obvious. The smug and sanctimonious tenor of their briefing makes that plain. But there is nothing sanctimonious about what is happening to Mr. Kelly.'
